Skip to main content

Table 1 Characteristics of the survey study population consisting of 176 CD and 162 UC participants

From: Patient experiences with the role of physical activity in inflammatory bowel disease: results from a survey and interviews

  CD UC Disease activity CD Disease activity UC
Remission Mild Moderate Remission Mild Moderate
Subjects, n (%) 176 (52.1) 162 (47.9) 127 (72.2) 31 (17.6) 18 (10.2) 110 (67.9) 36 (22.2) 16 (9.9)
Gender, n (%)
 Female 124 (70.5) 101 (62.3) 89 (70.1) 19 (61.3) 16 (88.9) 65 (59.1) 26 (72.2) 10 (62.5)
Age (years) 47.6 ± 15.6 50.0 ± 14.5 47.8 ± 15.7 47.2 ± 16.6 46.7 ± 13.9 49.8 ± 14.0 52.5 ± 15.4 45.4 ± 15.5
Age at diagnosis (years) 32.3 ± 14.6* 35.4 ± 14.1* 32.6 ± 15.1 30.9 ± 14.8 32.6 ± 9.4 34.3 ± 13.3 39.7 ± 15.5 33.4 ± 15.5
BMI (kg/m2) 24.9 ± 4.7 24.9 ± 3.8 25.0 ± 4.4 24.6 ± 4.8 25.0 ± 6.6 24.6 ± 3.5 25.4 ± 3.9 25.6 ± 5.6
Smoking, n (%)
 Never 127 (72.2) 125 (77.2) 99 (78.0)a 19 (61.3)a,b 9 (50.0)b 83 (75.5) 28 (77.8) 14 (87.5)
 Current 18 (10.2) 6 (3.7) 10 (7.9) 6 (19.4) 2 (11.1) 4 (3.6) 1 (2.8) 1 (6.3)
 Former 31 (17.6) 31 (19.1) 18 (14.2)a 6 (19.4)a,b 7 (38.9)b 23 (20.9) 7 (19.4) 1 (6.3)
Education level#, n (%)
 Low 40 (22.7) 32 (19.8) 27 (21.3) 8 (25.8) 5 (27.8) 21 (19.1) 8 (22.2) 3 (18.8)
 Middle 53 (30.1) 50 (30.9) 38 (29.9) 6 (19.4) 9 (50.0) 35 (31.8) 8 (22.2) 7 (43.8)
 High 83 (47.2) 80 (49.4) 62 (48.8) 17 (54.8) 4 (22.2) 54 (49.1) 20 (55.6) 6 (37.5)
Medication use, n (%)
 Mesalazines 29 (16.5)** 102 (63.0)** 22 (17.3) 4 (12.9) 3 (16.7) 69 (62.7) 20 (55.6) 13 (81.3)
 Corticosteroids 24 (13.6) 23 (14.2) 14 (11.0) 7 (22.6) 3 (16.7) 10 (9.1)a 9 (25.0)b 4 (25.0)a,b
 Immunosuppressants 76 (43.2)** 33 (20.4)** 55 (43.3) 14 (45.2) 7 (38.9) 20 (18.2) 8 (22.2) 5 (31.3)
 Biologicals 57 (32.4)** 28 (17.3)** 35 (27.6)a 12 (38.7)a,b 10 (55.6)b 11 (10.0)a 9 (25.0)a,b 8 (50.0)b
 Other 24 (13.6) 12 (7.4) 14 (11.0) 6 (19.4) 4 (22.2) 5 (4.5)a 3 (8.3)a,b 4 (25.0)b
 No medication use 36 (20.5) 29 (17.9) 30 (23.6) 5 (16.1) 1 (5.6) 23 (20.9) 6 (16.7) 0 (0.0)
Flare-ups in past year, n (%)
 None 91 (51.7)* 63 (38.9)* 79 (62.2)a 7 (22.6)b 5 (27.8)b 51 (46.4)a 10 (27.8)a,b 2 (12.5)b
 1–2 flare-ups 59 (33.5) 68 (42.0) 38 (29.9) 15 (48.4) 6 (33.3) 42 (38.2) 21 (58.3) 5 (31.3)
 3–4 flare-ups 9 (5.1)* 18 (11.1)* 2 (1.6)a 5 (16.1)b 2 (11.1)a,b 9 (8.2)a 3 (8.3)a 6 (37.5)b
 More than 4 flare-ups 17 (9.7) 13 (8.0) 8 (6.3)a 4 (12.9)a,b 5 (27.8)b 8 (7.3) 2 (5.6) 3 (18.8)
 Surgery, n (%) 60 (34.1)** 13 (8.0)** 41 (32.3) 10 (32.3) 9 (50.0) 6 (5.5) 6 (16.7) 1 (6.3)
  1. Data are presented as mean ± SD for normally distributed data. Categorical data is presented as n (%). *p < 0.05; **p < 0.01
  2. CD Crohn’s disease, UC ulcerative colitis, BMI body mass index
  3. #Education level: no education, primary or lower vocational education and lower general secondary education (low); secondary vocational education and higher general secondary education (middle); higher vocational education and university (high)
  4. abGroups with the same superscript letters do not differ significantly after post-hoc analyses using the Bonferroni test (p > 0.05)